# Combining Aspirin With Cilostazol or Clopidogrel in Large-vessel Minor Stroke or TIA

Study · id `cardio:ct-nct06591351` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06591351](<https://clinicaltrials.gov/study/NCT06591351>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06591351

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 870 participants.

## Technical summary

Registry record NCT06591351. Randomized; double masking; primary purpose treatment. Start 2022-05-01 (actual); primary completion 2024-09-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 870 participants (planned count; ClinicalTrials.gov record NCT06591351, source copy `cardio:ctgov-nct06591351-2024-09-19`, retrieved 2026-10-26)
- Started: 2022-05-01 (actual) (ClinicalTrials.gov record NCT06591351, source copy `cardio:ctgov-nct06591351-2024-09-19`, retrieved 2026-10-26)
- Primary completion: 2024-09-30 (anticipated) (ClinicalTrials.gov record NCT06591351, source copy `cardio:ctgov-nct06591351-2024-09-19`, retrieved 2026-10-26)
- Completion: 2024-10-10 (anticipated) (ClinicalTrials.gov record NCT06591351, source copy `cardio:ctgov-nct06591351-2024-09-19`, retrieved 2026-10-26)
- Countries: Egypt (ClinicalTrials.gov record NCT06591351, source copy `cardio:ctgov-nct06591351-2024-09-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06591351-2024-09-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: Combining Aspirin With Cilostazol or Clopidogrel in Large-vessel Minor Stroke or TIA
- Condition: Ischemic Stroke
- Intervention (Drug): Cilostazol 100 MG
- Intervention (Drug): Clopidogrel
- Lead sponsor: Kafrelsheikh University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record: Clopidogrel (`cardio:clopidogrel`)
- Registry lists this organization as the lead sponsor: Kafrelsheikh University (`cardio:org-kafrelsheikh-university`)

## Provenance

Content hash: af58dfaeb0ef99a4f1dc075b813f2025e28a3256d489cd3dfc01977232cdf88d
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
